News & Views

Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate

ASX, Clinical, News,

First Patient in Australia Dosed with Illuccix® – Telix’s Approved Prostate Cancer Imaging Agent 

ASX, News,

Telix today announces the first commercial dose in Australia of its prostate cancer imaging agent, Illuccix® (Kit for Preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC Injection), also known as 68Ga-PSMA-11...

First Patient Enrolled in ProstACT TARGET Study

ASX, Clinical, News,

Telix and GenesisCare, the largest provider of integrated cancer care in Australia, today announce that a first patient has been enrolled in the Phase II ProstACT TARGET study of Telix’s...

Final IPAX-1 Study Data Confirms Safety and Tolerability Profile for TLX101, Preliminary Efficacy Data

ASX, Clinical, News,

Telix today reports the final results from the IPAX-1 Ph I/II study of TLX101 therapy (4-L-[ ¹³¹I] iodo-phenylalanine, or ¹³¹I-IPA) in combination with external beam radiation therapy (EBRT) in recurrent...

Telix at AdMeTech Foundation’s 6th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer

Events, News,

We are pleased to announce that Telix is supporting AdMeTech Foundation’s 6th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer, to be held virtually from September 22-24...

Telix Japan – Telix Luncheon Seminar at WFNMB 2022

Events, News,

We are pleased to announce that Telix will be hosting a Luncheon Seminar at the 13th Congress of the World Federation of Nuclear Medicine and Biology (WFNMB), to be held at the Kyoto International Conference Center...

Targeted Alpha Therapy Candidate: Bladder Cancer Study Completes Enrolment

ASX, Clinical, News,

Telix and Nantes-based ATONCO S.A.S. (‘ATONCO’) today announced that the final patient has been dosed in a Phase I study of TLX250-CDx in patients with non-muscle invasive bladder cancer (NMIBC)...

Telix Half-Year Results 2022 and Shareholder Update

ASX, News,

Telix is pleased to present the Company’s financial results for the half-year ending 30 June 2022, together with a shareholder...

Telix and University of Queensland-led Consortium Awarded $5M Australian Research Council (ARC) Grant

ASX, News,

Telix today announces that it has been jointly awarded a $4.8 million Australian Research Council (ARC) grant to establish a new Industrial Transformation Research Program (ITRP) Hub as part of...